The Minister of Health Olivier Véran affirmed this Saturday that a vaccine will be ready for the spring of 2021. For its part, Sanofi announced a first estimate of the price of a dose of this remedy, which crossed a new stage on Thursday before commercialization. 

DECRYPTION

The coronavirus vaccine race will end in France "no later than spring 2021".

This is in any case what the Minister of Health Olivier Véran said this Saturday, during an interview.

A very short deadline, but the minister advises that the studies are progressing well.

France has also taken a new step this week, with the start last Thursday of clinical trials of the vaccine developed by the French Sanofi and its British partner, GSK.

>> LIVE -

Coronavirus: follow the evolution of the situation Saturday, September 5

A French vaccine much more expensive than the others?

So much so that a price for this highly anticipated vaccine, while the shadow of a second epidemic wave looms, is becoming clearer.

It will be less than 10 euros per dose, or five times more expensive than some competitors who promise it for around two euros.

A major difference that Olivier Bogillot, president of Sanofi France justifies in particular by the almost total absence of subcontracting on the part of his laboratory. 

CORONAVIRUS ESSENTIALS

> Covid-19: why the increase in the number of cases is greater than that of hospitalizations

> INVESTIGATION - Coronavirus: towards a new shortage of masks and gloves?

> Faced with the rebound of the Covid-19 epidemic, screening centers are overwhelmed

> Holidays: should grandparents worry about looking after their grandchildren?

> Coronavirus: the 5 mistakes not to make with your mask

300 million doses must be delivered to Europe in 2021

In any case, Sanofi hopes to achieve the 300 million doses promised to Europe in 2021. But this vaccine will certainly not be the first to be put on the market, since it is only in phase one. and two, when many competitors, especially Americans, are already in phase 3, the last before commercialization.

It is therefore a safe bet that the first vaccine validated by the WHO will not be French.

Moreover, the world health organization recalled that it would not endorse a vaccine against Covid-19 if it is not safe and effective.